<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805738</url>
  </required_header>
  <id_info>
    <org_study_id>163HBV15036</org_study_id>
    <nct_id>NCT02805738</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet and Viread® Tablet in Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to
      Evaluate the Efficacy and Safety of CKD-390 tablet
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to
      Evaluate the Efficacy and Safety of CKD-390 tablet and Viread® tablet in Chronic hepatitis B
      Patients Subjects will receive either a single oral dose of the test formulation(CKD-390) or
      a oral dose of the reference formulation(viread).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 20IU/mL)</measure>
    <time_frame>24weeks after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 20IU/mL)</measure>
    <time_frame>12, 36, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference between the baseline and at the 12, 24, 36, 48 week of HBV DNA level</measure>
    <time_frame>12, 24, 36, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who had normal ALT result</measure>
    <time_frame>12, 24, 36, 48weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg loss</measure>
    <time_frame>24, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg seroconversion</measure>
    <time_frame>24, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg loss</measure>
    <time_frame>24, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg seroconversion</measure>
    <time_frame>24, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed Virologic breakthrough</measure>
    <time_frame>12, 24, 36, 48 weeks after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-390</intervention_name>
    <description>CKD-390 1 Tablet (48 weeks)</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Tenofovir disoproxil aspartate 308.04mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>viread</intervention_name>
    <description>viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)</description>
    <arm_group_label>Active comparator Group</arm_group_label>
    <other_name>Tenofovir disoproxil fumarate 300mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female older than 19 years at the time of screening

          2. Patients who have chronic hepatitis B disease are taken Viried for 6 months

          3. Patients who show HBV DNA undetected(less than 20 IU/mL)

          4. Patients who show positive HBsAg

          5. Patients who show positive HBeAg or negative HBeAg

          6. Patients who fully understand the clinical trials after in-depth explanation, decided
             to join the clinical trials by their will and signed inform consent

        Exclusion Criteria:

          1. Patients who are not taken any anti-viral agents except Viread Tab

          2. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency
             virus (HIV)

          3. Patients who have seroperitoneum, icterus, hepatic encephalopathy, variceal hemorrhage
             or Patients with following value at screening

               -  total bilirubin &gt; Upper normal limit x 1.5

               -  prothrombin time(INR) &gt; Upper normal limit x 1.5

               -  platelets &lt; 75,000/ul

               -  serum albumin &lt; 3.0g/dl

          4. Patients who are estimated to have hepatocellular carcinoma (HCC) through imaging
             examination or showed alpha-fetoprotein(AFP) more than 50ng/mL

          5. Patients who show Creatinine Clearance &lt; 50 mL/min by calculating Cockcroft-Gault
             equation

          6. Patients with disease like heart failure, renal failure, pancreatitis that
             investigators consider ineligible for this study

          7. Patients who have other hepatic diseases like hematochromatosis, Wilson's disease,
             alcoholic cirrhosis, autoimmune hepatic diseases, α-1 antitrypsin deficit syndrome

          8. Patients with genetic disease like Galactose intolerance, lapplactase deficiency,
             Glucose-galactose malabsorption

          9. History of malignant tumor within 5 years

         10. Patients who take any other investigational product within 30 days

         11. Patients who have to administer immunosuppressants or Nephrotoxic drugs, Hepatotoxic
             drugs for period of Clinical Trial

         12. Pregnant, breast-feeding and childbearing age who don't use adequate contraception

         13. Patients who receive an organ transplant or bone marrow transplant or are going to
             received surgury

         14. History of allergic reaction to the investigational product

         15. Patients that investigators consider ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwan Sik lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangnam severance hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyengjun Lim, MD</last_name>
      <phone>82-31-412-6565</phone>
      <email>gudwns21@medimail.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunggue Hwang, MD</last_name>
      <phone>82-31-780-5213</phone>
      <email>sghwang@cha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joohyun Sohn, MD</last_name>
      <phone>82-31-560-2225</phone>
      <email>sonjh@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Sung Lee, MD</last_name>
      <phone>82-31-910-7823</phone>
      <email>jsleemd@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University of Medicine and Science Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Busan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heonju Lee, MD</last_name>
      <phone>82-53-620-3834</phone>
      <email>heonjulee@yu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byengseok Lee, MD</last_name>
      <phone>82-2-2019-3314</phone>
      <email>leeks519@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byungcher Song, MD</last_name>
      <phone>82-64-717-1643</phone>
      <email>drsong@jejunu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwan Sik Lee, MD</last_name>
      <phone>82-2-2019-2332</phone>
      <email>leeks519@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hosptial</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jihoon Kim, MD</last_name>
      <phone>82-2-2626-3011</phone>
      <email>kjhhepar@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Do Young Kim, MD</last_name>
      <phone>82-2-2228-0525</phone>
      <email>dyk1025@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>tenofovir</keyword>
  <keyword>CKD-390</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

